NextCure
NXTC
52 hedge funds and large institutions have $41.8M invested in NextCure in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 15 reducing their positions, and 4 closing their positions.
62% more call options, than puts
Call options by funds: $1.11M | Put options by funds: $687K
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
2% more funds holding
Funds holding: 51 → 52 (+1)
0.24% more ownership
Funds ownership: 4.34% → 4.58% (+0.24%)
13% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 15
39% less capital invested
Capital invested by funds: $67.9M → $41.8M (-$26.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$3.37M |
| 2 |
Millennium Management
New York
|
+$429K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$343K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$225K |
| 5 |
Two Sigma Advisers
New York
|
+$211K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$511K |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$336K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$297K |
| 4 |
Renaissance Technologies
New York
|
-$262K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$153K |
NXTC Hedge Fund Activity: Q3 2022 in Review
52 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q3 2022, worth a combined $41.8M — down 39% from $67.9M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NXTC positions and 4 closed out — a net gain of 1 holder — while 13 added to existing stakes and 15 trimmed.
The largest buyer was K2 Principal Fund, adding an estimated $3.37M. The largest seller was Assenagon Asset Management, exiting entirely with an estimated $511K sold.
- 52 institutional investors held NextCure (NXTC) as of Q3 2022, up from 51 in Q2 2022.
- Funds reported $41.8M of NextCure stock for Q3 2022, down 39% quarter-over-quarter.
- 5 funds opened new NextCure positions in Q3 2022 and 4 closed out, a net change of +1 holder.
- The largest NextCure buyer in Q3 2022 was K2 Principal Fund, an estimated $3.37M added.
- The largest NextCure seller in Q3 2022 was Assenagon Asset Management, an estimated $511K sold.
Based on aggregated 13F filings for Q3 2022.